Half Year Results 

Vectura embarks on latest strategy overhaul

Vectura embarks on latest strategy overhaul

Vectura (VEC) has undergone a disconcerting number of identity changes since its acquisition of SkyePharma in 2016. The most recent strategy update – to focus on partnered projects and medical development services – is already having an impact on the numbers. In the first half of 2019, group research and development costs fell 10 per cent to £24.5m, which helped more than halve operating losses and boost adjusted cash profits by 11 per cent to £25m.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now